HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose over 11% in morning trading; third-quarter net profit increased nearly 90% year-on-year and 12% quarter-on-quarter.

Jiangsu Hengrui Pharmaceuticals (01276) rose over 11% in morning trading. As of press time, it was up 8.63% at HK$48.58, with turnover of HK$112 million. On the news front, Jiangsu Hengrui Pharmaceuticals announced that its third-quarter operating revenue was RMB8.953 billion, up 20.55% year-on-year; net profit attributable to shareholders was RMB2.458 billion, up 88.92% year-on-year and up 12% quarter-on-quarter. In the first three quarters, the company achieved operating revenue of RMB24.409 billion, up 5.26% year-on-year; net profit attributable to shareholders was RMB6.923 billion, up 20.38% year-on-year. It is worth noting that recently, Jiangsu Hengrui Pharmaceuticals received a notice from the National Medical Products Administration. The company recently received a notice from the NMPA that remimazolam besylate for injection has been approved for a new indication, for sedation during mechanical ventilation in intensive care. The drug had previously been approved in China for sedation and anesthesia in non-tracheal intubation procedures/operations, and for the induction and maintenance of general anesthesia.